Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
Krečak, I., Skorić, I., Čengić, M., Krečak, F. & Skelin, M. (2022). Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582
Krečak, Ivan, et al. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science, 2022. https://doi.org/10.1016/j.transci.2022.103582
Krečak, Ivan, Ivana Skorić, Marina Čengić, Filip Krečak and Marko Skelin. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science (2022). https://doi.org/10.1016/j.transci.2022.103582
Krečak, I., et al. (2022) 'Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim', Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582
Krečak I, Skorić I, Čengić M, Krečak F, Skelin M. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science [Internet]. 2022 October [cited 2024 December 03]. doi: 10.1016/j.transci.2022.103582
I. Krečak, I. Skorić, M. Čengić, F. Krečak and M. Skelin, "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim", Transfusion and Apheresis Science, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:541304. [Accessed: 03 December 2024]
